ChatGPT & RLHF Co-Inventor Launches Jev, Claiming 20-200x Faster Decisions

Not Boring (Packy McCormick) · rss · 2026-09-18

Packy McCormick's Weekly Dose of Optimism #211 highlights:

TypeSafe launches Jev: Diogo Almeida, co-inventor of the research behind ChatGPT and RLHF, unveiled Jev, a model for predefined decision tasks (ticket routing, fraud checks, churn prediction). It returns decisions and probabilities in parallel without token-by-token generation; company-reported numbers claim 20-200x faster responses and 40-400x lower costs than frontier models, pending third-party benchmarks.
First treatment for 'Childhood Alzheimer's' approved: The FDA approved Ultragenyx's gene therapy Fayuvi for Sanfilippo syndrome type A—a one-time AAV9 infusion. In the pivotal trial, 17 treated kids scored 23.5 points higher on a cognitive scale than an untreated natural-history cohort, with 8 years of follow-up. Previously rejected over manufacturing issues, now cleared with shipments expected in 30-60 days.
Positive Phase III lung cancer results: Amgen and AstraZeneca's DeLLphi-305 trial (563 patients) showed tarlatamab plus durvalumab significantly improved overall survival in extensive-stage small-cell lung cancer—encouraging news for podcaster Ben Wilson, a stage 4 cancer patient seeking the treatment.
Natural General Intelligence: Lowercarbon partner Ryan Orbuch argues we've mapped only 27% of the ocean floor with modern sonar and should gather planetary-scale data and build models to understand Earth, analogous to how models tame complex biology.

(This issue is sponsored by document-parsing company Reducto, whose r-1 model claims up to 20% fewer parsing errors at 1¢ per page.)

More from Companies & People